Efficacy of citicoline as a supplement in glaucoma patients: A systematic review
PLOS ONE · 28.09.2023 · 18 (9) · e0291836
DOI: 10.1371/journal.pone.0291836 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift PLOS ONE, online erschienen am 28.09.2023. Verfasst von Julia Prinz und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, RWTH Aachen University, Aachen, Germany. Hauptthemen laut MEDLINE: Glaucoma, Open-Angle, Glaucoma. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Glaucoma is a leading cause of irreversible blindness worldwide. Retinal ganglion cells (RGC), the neurons that connect the eyes to the brain, specifically die in glaucoma, leading to blindness. Elevated intraocular pressure (IOP) is the only modifiable risk factor, however, many patients progress despite excellent IOP control. Thus, alternative treatment strategies to prevent glaucoma progression are an unmet need. Citicoline has demonstrated neuroprotective properties in central neurodegenerative diseases. However, conclusive evidence of the effect of citicoline on glaucoma progression is missing. This systematic review investigates first-time the therapeutic potential of citicoline in glaucoma patients.
Methods
The present study was conducted according to the PRISMA 2020 statement. PubMed, Web of Science, Google Scholar, and Embase were accessed in July 2023 to identify all clinical studies investigating the efficacy of citicoline on IOP, the mean deviation of the 24–2 visual field testing (MD 24–2), retinal nerve fibre layer (RNFL), and the pattern electroretinogram (PERG) P50-N95 amplitude in glaucoma patients. The risk of bias was assessed using the Review Manager 5.3 software (The Nordic Cochrane Collaboration, Copenhagen) and the Risk of Bias in Non-randomised Studies of Interventions (ROBINS-I) tool.
Results
Ten studies were eligible for this systematic review, including 424 patients. The mean length of the follow-up was 12.1 ± 11.6 months. The overall risk of bias was low to moderate. The mean age of the patients was 56.7 years. There were no significant differences in the IOP, MD 24–2, RNFL, or PERG P50-N95 amplitude between patients receiving citicoline and the control group. There was no improvement from baseline to the last follow-up in IOP, MD 24–2, RNFL, or PERG P50-N95 amplitude.
Conclusion
There is a lack of sufficient evidence to support that citicoline slows the progression of glaucoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, RWTH Aachen University, Aachen, Germany.
- Department of Ophthalmology, Faculty of Medicine and University Hospital of Cologne, Cologne, Germany.
- Department of Orthopaedic and Trauma Surgery, RWTH Aachen University, Aachen, Germany.
- Department of Orthopedics and Trauma Surgery, Academic Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy.
ORCID-Profile: Julia Prinz, Verena Prokosch
Zitieren
APA
Prinz, J., Prokosch, V., Liu, H., Walter, P., Fuest, M., & Migliorini, F. (2023). Efficacy of citicoline as a supplement in glaucoma patients: A systematic review. PLOS ONE, 18(9), e0291836. https://doi.org/10.1371/journal.pone.0291836
Vancouver
Prinz J, Prokosch V, Liu H, Walter P, Fuest M, Migliorini F. Efficacy of citicoline as a supplement in glaucoma patients: A systematic review. PLOS ONE. 2023;18(9):e0291836. doi:10.1371/journal.pone.0291836
BibTeX
@article{Prinz2023,
author = {Prinz, Julia and Prokosch, Verena and Liu, Hanhan and Walter, Peter and Fuest, Matthias and Migliorini, Filippo},
title = {Efficacy of citicoline as a supplement in glaucoma patients: A systematic review},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {9},
pages = {e0291836},
doi = {10.1371/journal.pone.0291836}
}
EUVIMED